Gland Pharma breaks out from a consolidation range, indicating bullish momentum. The stock, supported at Rs 1,600 in October 2024 and resisted at Rs 1,850, is now trading above key moving averages. Experts suggest buying for a target range of Rs 2,175-2,200 with a stop loss of Rs 1,710.
